Dr. Perl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
12-154 PCAM South Tower
Philadelphia, PA 19104Phone+1 215-662-4794
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2001 - 2003
- University of California (San Francisco)Residency, Internal Medicine, 1997 - 2000
- Icahn School of Medicine at Mount SinaiClass of 1997
Certifications & Licensure
- CA State Medical License 1999 - Present
- PA State Medical License 2003 - 2026
- MD State Medical License 2002 - 2003
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) Start of enrollment: 2010 Jul 01
- Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2011 Nov 21
Publications & Presentations
PubMed
- Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.Margaret Rowe, Daria Babushok, Martin Carroll, Alison Carulli, Noelle Frey
European Journal of Haematology. 2025-04-01 - Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem dup...Richard F Schlenk, Pau Montesinos, Hee-Je Kim, Antonio Romero-Aguilar, Radovan Vrhovac
Haematologica. 2025-03-13 - Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial.Anand P Jillella, Sandra J Lee, Jessica K Altman, Selina M Luger, Martin S Tallman
JAMA Oncology. 2025-02-27
Journal Articles
- Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 InhibitorsAlexander Perl, MD, Clinical Cancer Research
- Phase 2b Study of Two Dosing Regimens of Quizartinib Monotherapy in FLT3-ITD Mutated, Relapsed or Refractory AMLAlexander E Perl, Mark J Levis, Stuart L Goldberg, Martin S Tallman, Hagop M Kantarjian, Gary J Schiller, Blood
Abstracts/Posters
- Characterization of Response and Transfusion Independence in Patients with FLT3-Internal Tandem Duplication (FLT3-ITD)_Mutated Relapsed/Refractory Acute Myeloid Leukem...Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Clinically Relevant AbstractAlexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)...Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b StudyClinically Relevant Abstract61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Treating Acute Myeloid Leukemia: Case Challenges and Emerging Therapies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Longitudinal Monitoring of AML Tumors with High-Throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Gilteritinib Shows Efficacy in Patients with Acute Myeloid Leukemia with Prior Tyrosine Kinase Inhibitor TherapySeptember 10th, 2021
- Novel Agents Hold Promise for Frontline AML TreatmentOctober 28th, 2020
- Astellas Presents New Data on XOSPATA® (Gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual MeetingDecember 2nd, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: